Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Watch

NCOA2 Drives Development of Castration-Resistant Prostate Cancer

DOI: 10.1158/2159-8290.CD-RW2014-221 Published December 2014
  • Article
  • Info & Metrics
Loading
  • Major finding: Induction of NCOA2 by androgen deprivation enhances prostate cancer progression and metastasis.

  • Mechanism: NCOA2-mediated transcriptional regulation activates PI3K and MAPK signaling to promote CRPC.

  • Impact: Inhibition of NCOA2-driven signaling combined with androgen deprivation therapy may limit CRPC.

Resistance to androgen deprivation therapy (ADT) results in the outgrowth of castration-resistant prostate cancer (CRPC) and increased metastatic spread. Although PI3K–AKT and MAPK signaling has been implicated in CRPC, the mechanisms that mediate activation of these pathways and progression to CRPC are not completely understood. Nuclear receptor coactivator 2 (NCOA2) is commonly amplified or overexpressed in prostate cancer and is associated with tumor relapse following ADT, prompting Qin, Lee, and colleagues to investigate its potential role in CRPC. Prostate-specific overexpression of NCOA2 was sufficient to initiate prostate epithelial hyperplasia and development of low-grade prostatic intraepithelial neoplasia (PIN) in mice, supporting an oncogenic role for NCOA2. Furthermore, NCOA2 overexpression accelerated the progression of Pten-deficient tumors to high-grade PIN and invasive adenocarcinoma and resulted in enhanced metastatic spread. Ncoa2 expression was suppressed by androgen receptor signaling and induced by androgen deprivation; deletion of Ncoa2 in castrated mice inhibited androgen-independent proliferation and prevented development of CRPC and metastatic disease, suggesting that NCOA2 upregulation in response to ADT is required for CRPC. Mechanistically, NCOA2 directly repressed the transcription of genes that negatively regulate PI3K–AKT signaling, including Phlpp1, Fkbp5, and Pten, and induced the transcription of genes that stimulate the MAPK pathway, including Map3k1 and Prex1, resulting in increased activation of these pathways in prostate tumors and progression to CRPC. Consistent with these findings, expression of an NCOA2 gene expression signature was positively correlated with activation of PI3K and MAPK signaling in human prostate cancer samples and was elevated in patients with metastatic prostate cancer. In addition, high expression of NCOA2-regulated genes was correlated with shorter time to tumor recurrence and decreased survival. These findings identify NCOA2 as a driver of CRPC and prostate cancer metastasis and suggest that inhibition of NCOA2-mediated signaling may enhance the efficacy of ADT.

Qin J, Lee HJ, Wu SP, Lin SC, Lanz RB, Creighton CJ, et al. Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer. J Clin Invest 2014 Oct 8 [Epub ahead of print].

  • ©2014 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 4 (12)
December 2014
Volume 4, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
NCOA2 Drives Development of Castration-Resistant Prostate Cancer
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
NCOA2 Drives Development of Castration-Resistant Prostate Cancer
Cancer Discov December 1 2014 (4) (12) OF16; DOI: 10.1158/2159-8290.CD-RW2014-221

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
NCOA2 Drives Development of Castration-Resistant Prostate Cancer
Cancer Discov December 1 2014 (4) (12) OF16; DOI: 10.1158/2159-8290.CD-RW2014-221
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Epstein–Barr Virus–Induced Antitumor Immune Response May Be Harnessable
  • FBXO44 Silences Repetitive Elements during DNA Replication in Cancer
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
Show more Research Watch

Prostate Cancer

  • Developmental Programs Are Reactivated in Prostate Cancer Metastasis
  • Remaining Prostate Luminal Cells Regenerate after Androgen Deprivation
  • DDR-Defective Metastatic Prostate Cancers Are Susceptible to Olaparib
Show more Prostate Cancer
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement